These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 2248616)

  • 1. Plasma apolipoprotein E, high density lipoprotein1 (HDL1) and urinary mevalonate excretion in pancreatectomized diabetic dogs: effects of insulin and lovastatin.
    Gleeson JM; Hejazi JS; Kwong L; Chan IF; Le T; Alberts AW; Wilson DE
    Atherosclerosis; 1990 Sep; 84(1):1-12. PubMed ID: 2248616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apolipoprotein E-containing lipoproteins and lipoprotein remnants in experimental canine diabetes.
    Wilson DE; Chan IF; Elstad NL; Peric-Golia L; Hejazi J; Albu DS; Cutfield R
    Diabetes; 1986 Aug; 35(8):933-42. PubMed ID: 3732634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intestinal and hepatic cholesterogenesis in hypercholesterolemic dyslipidemia of experimental diabetes in dogs.
    Kwong LK; Feingold KR; Peric-Golia L; Le T; Karkas JD; Alberts AW; Wilson DE
    Diabetes; 1991 Dec; 40(12):1630-9. PubMed ID: 1756903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction in plasma low-density lipoprotein cholesterol and urinary mevalonic acid by lovastatin in patients with heterozygous familial hypercholesterolemia.
    Pappu AS; Illingworth DR; Bacon S
    Metabolism; 1989 Jun; 38(6):542-9. PubMed ID: 2725293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formation of cholesterol- and apoprotein E-enriched high density lipoproteins in vitro.
    Gordon V; Innerarity TL; Mahley RW
    J Biol Chem; 1983 May; 258(10):6202-12. PubMed ID: 6343371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contrasting effects of lovastatin and cholestyramine on low-density lipoprotein cholesterol and 24-hour urinary mevalonate excretion in patients with heterozygous familial hypercholesterolemia.
    Pappu AS; Illingworth DR
    J Lab Clin Med; 1989 Nov; 114(5):554-62. PubMed ID: 2809398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dietary effects on serum lipoproteins of dyslipoproteinemic baboons with high HDL1.
    McGill HC; McMahan CA; Kushwaha RS; Mott GE; Carey KD
    Arteriosclerosis; 1986; 6(6):651-63. PubMed ID: 3096264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolism of larger high density lipoproteins accumulating in some families of baboons fed a high cholesterol and high saturated fat diet.
    Kushwaha RS; Foster DM; Murthy VN; Carey KD; McGill HC
    J Lipid Res; 1989 Aug; 30(8):1147-59. PubMed ID: 2504862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increases in dietary cholesterol and fat raise levels of apoprotein E-containing lipoproteins in the plasma of man.
    Cole TG; Patsch W; Kuisk I; Gonen B; Schonfeld G
    J Clin Endocrinol Metab; 1983 Jun; 56(6):1108-15. PubMed ID: 6841553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of apolipoprotein E-containing lipoproteins in abetalipoproteinemia.
    Blum CB; Deckelbaum RJ; Witte LD; Tall AR; Cornicelli J
    J Clin Invest; 1982 Dec; 70(6):1157-69. PubMed ID: 6294137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia.
    Pappu AS; Bacon SP; Illingworth DR
    J Lab Clin Med; 2003 Apr; 141(4):250-6. PubMed ID: 12677170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apolipoprotein E-rich HDL in patients with homozygous familial hypercholesterolemia.
    Keidar S; Ostlund RE; Schonfeld G
    Atherosclerosis; 1990 Oct; 84(2-3):155-63. PubMed ID: 2126436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New developments in lipid-lowering therapy: the role of inhibitors of hydroxymethylglutaryl-coenzyme A reductase.
    Tobert JA
    Circulation; 1987 Sep; 76(3):534-8. PubMed ID: 3113763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lovastatin versus bezafibrate: efficacy, tolerability, and effect on urinary mevalonate.
    Beil FU; Schrameyer-Wernecke A; Beisiegel U; Greten H; Karkas JD; Liou R; Alberts AW; Eckardt HG; Till AE
    Cardiology; 1990; 77 Suppl 4():22-32. PubMed ID: 2073669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of dyslipidemia in non-insulin-dependent diabetes mellitus with lovastatin.
    Garg A; Grundy SM
    Am J Cardiol; 1988 Nov; 62(15):44J-49J. PubMed ID: 3055923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [On the etiology of diabetic hyperlipidemia from the aspects of the metabolism of ApoHDL (author's transl)].
    Keimatsu M
    Hokkaido Igaku Zasshi; 1981 Sep; 56(5):557-69. PubMed ID: 7319464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urinary mevalonate excretion rate in type 2 diabetes: role of metabolic control.
    Scoppola A; Montecchi FR; Menzinger G; Lala A
    Atherosclerosis; 2001 Jun; 156(2):357-61. PubMed ID: 11395032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of insulin on plasma mevalonate concentrations in man.
    Lala A; Scoppola A; Ricci A; Frontoni S; Gambardella S; Menzinger G
    Ann Nutr Metab; 1994; 38(5):257-62. PubMed ID: 7710260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction in plasma apolipoprotein E and HDL1 levels in rats with essential fatty acid deficiency.
    Ney DM; Ziboh VA; Schneeman BO
    J Nutr; 1987 Dec; 117(12):2016-20. PubMed ID: 3121811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel large apolipoprotein E-containing lipoproteins of density 1.006-1.060 g/ml in human cerebrospinal fluid.
    Guyton JR; Miller SE; Martin ME; Khan WA; Roses AD; Strittmatter WJ
    J Neurochem; 1998 Mar; 70(3):1235-40. PubMed ID: 9489746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.